Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009.
3/5 보강
TL;DR
Alopecia Areata is characterized by patchy, nonscarring, autoimmune-mediated hair loss, although many aspects of AA pathogenesis are unknown, and the scalp is most commonly involved in clinically treated AA.
📑 코퍼스 인용 관계
· 인용됨 104
📑 인용한 논문 (6) ▾
- The Psychiatric Burden in Alopecia Areata: A Propensity-Matched Cohort Study. Dermatology and therapy · 2026
- The Evolving Global Burden of Alopecia Areata in Young Adults: High-Income Nations Bear th… Annals of dermatology · 2026
- Squaric Acid Dibutylester Promotes Innate Immune-Driven Hair Growth with CD206 Macrophage … JID innovations : skin science from molecules to population health · 2026
- Analysis of trichoscopic images using deep neural networks for the diagnosis and activity … Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Are… Dermatology and therapy · 2025
- Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universali… Cureus · 2025
연도별 인용 (2014–2026) · 합계 326
OpenAlex 토픽 ·
Hair Growth and Disorders
Autoimmune Bullous Skin Diseases
Dermatology and Skin Diseases
Alopecia Areata is characterized by patchy, nonscarring, autoimmune-mediated hair loss, although many aspects of AA pathogenesis are unknown, and the scalp is most commonly involved in clinically trea
APA 7
Mirzoyev, S. A., Schrum, A. G., Davis, M. D. P., & Torgerson, R. R. (2014). Lifetime incidence risk of alopecia areata estimated at 2.1% by rochester epidemiology project, 1990-2009.. The Journal of investigative dermatology, 134(4), 1141-1142. https://doi.org/10.1038/jid.2013.464
Vancouver
Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. Jour. inve. derm.. 2014;134(4):1141-1142. doi:10.1038/jid.2013.464
AMA 11
Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. Jour. inve. derm.. 2014;134(4):1141-1142. doi:10.1038/jid.2013.464
Chicago
Mirzoyev, S. A., Schrum, A. G., Davis, M. D. P., and Torgerson, R. R.. 2014. "Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009." The Journal of investigative dermatology 134 (4): 1141-1142. https://doi.org/10.1038/jid.2013.464
MLA 9
Mirzoyev, S. A., et al. "Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009." The Journal of investigative dermatology, vol. 134, no. 4, 2014, pp. 1141-1142. doi:10.1038/jid.2013.464.
PMID
24202232 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 8/8 (100%)
· 참조 0편 · 후속 8편
이 논문을 인용한 후속 연구 20
- Alopecia areata.
- Epidemiology and burden of alopecia areata: a systematic review.
- Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options.
- Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
- "'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so …
- Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature.
- Frequency of the Types of Alopecia at Twenty-Two Specialist Hair Clinics: A Multicenter Study.
- Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strate…
- The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implicatio…
- The epidemiology of alopecia areata: a population-based cohort study in UK primary care.
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis…
- A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States.
- Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis.
- Objective outcome measures: Collecting meaningful data on alopecia areata.
- Prevalence and Clinical Characteristics of Alopecia Areata at a Tertiary Care Center in Saudi Arabia…
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.
- The current state of knowledge of the immune ecosystem in alopecia areata.
- Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with A…
- Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire.
📖 전문 본문 읽기 PMC JATS · ~7 KB · 영문
Letter
Letter
Alopecia Areata (AA) is characterized by patchy, nonscarring, autoimmune-mediated hair loss, although many aspects of AA pathogenesis are unknown (Gilhar et al., 2012). The scalp is most commonly involved in clinically treated AA, but any hair-bearing surface of the body may be affected (Wasserman et al., 2007). Males and females of any age and hair color can have AA (Finner, 2011; Kyriakis et al., 2009). According to the First National Health and Nutrition Examination Survey conducted in the early 1970s, AA is fairly common; it was estimated to affect about 2 of every 1,000 people in the United States (Safavi, 1992). Dermatologists encounter AA in 0.7% to 4.0% of their patient populations (Price, 1991; Sharma et al., 1996; Tan et al., 2002). A previous study reported by Mayo Clinic and National Institutes of Health (Safavi et al., 1995) showed that the overall incidence of AA in Olmsted County, Minnesota, was 20.2 per 100,000 person-years from 1975 through 1989. A similar incidence rate for both sexes with a lifetime risk of 1.7% was observed.
The purpose of the current study was to continue the previous analysis and document the most current lifetime incidence risk of AA. Clinical data accessed via the Rochester Epidemiology Project (REP) provided a retrospective review of all patients resident in Olmsted County, Minnesota, that were newly diagnosed with AA from 1990 through 2009. Of 530 qualifying patients, the mean age at diagnosis was 33.6 years (median, 33 years; range, 0–90 years). Additional features for the study cohort are summarized in Table 1. The mean age at diagnosis of AA for males was 31.5 years (median, 31 years; range, 0.5–80 years); for females, it was 36.2 years (median, 36.4 years; range, 1.8–90.7 years).
As shown in Table 2, the age- and sex-adjusted incidence of AA was 20.9 per 100,000 person-years (95% CI, 19.1–22.6). Cumulative AA incidence increased almost linearly with age (0.3%, 20 years; 0.6%, 30 years; 0.8%, 40 years; 1.1%, 50 years; 1.4%, 60 years), while cumulative lifetime incidence was 2.1%. Age-adjusted incidence was 21.3 per 100,000 person-years (95% CI, 18.8–23.9) for females and 20.2 per 100,000 person-years (95% CI, 17.7–22.6) for males (no significant difference, P = 0.77), supporting the observation that both females and males display similar susceptibility to AA.
At 2.1%, the cumulative lifetime incidence of AA from this recent 20-year period (1990–2009) was slightly higher than 1.7% observed in the older study (years 1975–1989) (Safavi et al., 1995). Similarly, REP data analyzed in studies of other autoimmune-associated diseases have shown that incidence of rheumatoid arthritis (Myasoedova et al., 2010) and systemic lupus erythematosis (Uramoto et al., 1999) have also increased in the region in recent years. These data do not refute the hypothesis that autoimmune disease incidence may be rising, generally.
The current study also confirms that AA does not exhibit a gender bias (Muller and Winkelmann, 1963). Although some studies have reported AA to be slightly more common in females (Goh et al., 2006; Kyriakis et al., 2009; Tan et al., 2002), such findings might be attributable to a greater cultural awareness of and sensitivity to hair loss among females that prompts them to seek medical attention. Interestingly, in Turkey, a higher male: female ratio (1.6:1) was reported for patients with AA (Kavak et al., 2008). The authors explained the likely artificial skew toward male patients in the context of religious practices and suggested that the headscarves worn by women may have allowed some to avoid seeking medical attention for hair loss. The predominantly white patient population in the current study is reflective of the geographic race distribution and is not a sign of racial differences in AA prevalence. In conclusion, we assessed the incidence of AA in Olmsted County, Minnesota, during a recent 20-year period (1990–2009), and found that the lifetime incidence risk was 2.1%.
Alopecia Areata (AA) is characterized by patchy, nonscarring, autoimmune-mediated hair loss, although many aspects of AA pathogenesis are unknown (Gilhar et al., 2012). The scalp is most commonly involved in clinically treated AA, but any hair-bearing surface of the body may be affected (Wasserman et al., 2007). Males and females of any age and hair color can have AA (Finner, 2011; Kyriakis et al., 2009). According to the First National Health and Nutrition Examination Survey conducted in the early 1970s, AA is fairly common; it was estimated to affect about 2 of every 1,000 people in the United States (Safavi, 1992). Dermatologists encounter AA in 0.7% to 4.0% of their patient populations (Price, 1991; Sharma et al., 1996; Tan et al., 2002). A previous study reported by Mayo Clinic and National Institutes of Health (Safavi et al., 1995) showed that the overall incidence of AA in Olmsted County, Minnesota, was 20.2 per 100,000 person-years from 1975 through 1989. A similar incidence rate for both sexes with a lifetime risk of 1.7% was observed.
The purpose of the current study was to continue the previous analysis and document the most current lifetime incidence risk of AA. Clinical data accessed via the Rochester Epidemiology Project (REP) provided a retrospective review of all patients resident in Olmsted County, Minnesota, that were newly diagnosed with AA from 1990 through 2009. Of 530 qualifying patients, the mean age at diagnosis was 33.6 years (median, 33 years; range, 0–90 years). Additional features for the study cohort are summarized in Table 1. The mean age at diagnosis of AA for males was 31.5 years (median, 31 years; range, 0.5–80 years); for females, it was 36.2 years (median, 36.4 years; range, 1.8–90.7 years).
As shown in Table 2, the age- and sex-adjusted incidence of AA was 20.9 per 100,000 person-years (95% CI, 19.1–22.6). Cumulative AA incidence increased almost linearly with age (0.3%, 20 years; 0.6%, 30 years; 0.8%, 40 years; 1.1%, 50 years; 1.4%, 60 years), while cumulative lifetime incidence was 2.1%. Age-adjusted incidence was 21.3 per 100,000 person-years (95% CI, 18.8–23.9) for females and 20.2 per 100,000 person-years (95% CI, 17.7–22.6) for males (no significant difference, P = 0.77), supporting the observation that both females and males display similar susceptibility to AA.
At 2.1%, the cumulative lifetime incidence of AA from this recent 20-year period (1990–2009) was slightly higher than 1.7% observed in the older study (years 1975–1989) (Safavi et al., 1995). Similarly, REP data analyzed in studies of other autoimmune-associated diseases have shown that incidence of rheumatoid arthritis (Myasoedova et al., 2010) and systemic lupus erythematosis (Uramoto et al., 1999) have also increased in the region in recent years. These data do not refute the hypothesis that autoimmune disease incidence may be rising, generally.
The current study also confirms that AA does not exhibit a gender bias (Muller and Winkelmann, 1963). Although some studies have reported AA to be slightly more common in females (Goh et al., 2006; Kyriakis et al., 2009; Tan et al., 2002), such findings might be attributable to a greater cultural awareness of and sensitivity to hair loss among females that prompts them to seek medical attention. Interestingly, in Turkey, a higher male: female ratio (1.6:1) was reported for patients with AA (Kavak et al., 2008). The authors explained the likely artificial skew toward male patients in the context of religious practices and suggested that the headscarves worn by women may have allowed some to avoid seeking medical attention for hair loss. The predominantly white patient population in the current study is reflective of the geographic race distribution and is not a sign of racial differences in AA prevalence. In conclusion, we assessed the incidence of AA in Olmsted County, Minnesota, during a recent 20-year period (1990–2009), and found that the lifetime incidence risk was 2.1%.
Methods
Methods
Clinical Setting
This study was approved by the institutional review boards of Mayo Clinic and Olmsted Medical Center. The REP medical records system links information from all health care providers in Olmsted County, Minnesota. It includes medical records for all residents of the county, regardless of where care was received in the county. The relative geographic isolation of Olmsted County residents from other medical institutions provides a unique opportunity to conduct population-based analyses (St Sauver et al., 2012).
Patient Selection
The REP databank was used to identify Olmsted County residents with their first lifetime diagnosis of AA established from 1990 through 2009. Medical records of identified patients were reviewed and data were abstracted. Each diagnosis was validated by a physician and documented in the medical record.
Statistical Methods
Incidence rates per 100,000 person-years were calculated using incident cases of AA as the numerator and age- and sex-specific estimates of the county population as the denominator. The populations at risk for the years 1990–2000 were estimated using census data from 1990 and 2000, with linear interpolation for intercensal years. The populations at risk for the years 2001–2009 were obtained from US Intercensal Estimates (United States Census Bureau). Because the population of Olmsted County is nearly all white, incidence rates were directly age- and sex-adjusted to the structure of the 2000 US white population. Incident cases were grouped on the basis of age at diagnosis (0–9, 10–19, 20–29, 30–39, 40–49, 50–59, and ≥60 years) and year of diagnosis (1990–1994–1995–1999–2000–2004, and 2005–2009). The relationships of age at diagnosis, sex, and year of diagnosis with the incidence of AA were assessed by fitting Poisson regression models using the SAS procedure GENMOD (SAS Institute Inc). P values less than 0.05 were considered statistically significant.
Clinical Setting
This study was approved by the institutional review boards of Mayo Clinic and Olmsted Medical Center. The REP medical records system links information from all health care providers in Olmsted County, Minnesota. It includes medical records for all residents of the county, regardless of where care was received in the county. The relative geographic isolation of Olmsted County residents from other medical institutions provides a unique opportunity to conduct population-based analyses (St Sauver et al., 2012).
Patient Selection
The REP databank was used to identify Olmsted County residents with their first lifetime diagnosis of AA established from 1990 through 2009. Medical records of identified patients were reviewed and data were abstracted. Each diagnosis was validated by a physician and documented in the medical record.
Statistical Methods
Incidence rates per 100,000 person-years were calculated using incident cases of AA as the numerator and age- and sex-specific estimates of the county population as the denominator. The populations at risk for the years 1990–2000 were estimated using census data from 1990 and 2000, with linear interpolation for intercensal years. The populations at risk for the years 2001–2009 were obtained from US Intercensal Estimates (United States Census Bureau). Because the population of Olmsted County is nearly all white, incidence rates were directly age- and sex-adjusted to the structure of the 2000 US white population. Incident cases were grouped on the basis of age at diagnosis (0–9, 10–19, 20–29, 30–39, 40–49, 50–59, and ≥60 years) and year of diagnosis (1990–1994–1995–1999–2000–2004, and 2005–2009). The relationships of age at diagnosis, sex, and year of diagnosis with the incidence of AA were assessed by fitting Poisson regression models using the SAS procedure GENMOD (SAS Institute Inc). P values less than 0.05 were considered statistically significant.
출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.